Arbutus Biopharma Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lindsay Androski
- Full Time Employees
- 44
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 701 Veterans Circle Warminster PA United States of America 18974
- IPO Date
- Jul 26, 2007
- CIK
- 0001447028
- Website
- arbutusbio.com
- Similar Companies
- Business
- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company headquartered in Warminster, Pennsylvania, leverages its virology expertise to develop novel therapeutics targeting infectious diseases, with a primary focus on achieving a functional cure for chronic hepatitis B virus (cHBV) through multi-faceted combination regimens; its core pipeline includes the proprietary GalNAc-conjugated RNAi therapeutic imdusiran (AB-729), which suppresses viral DNA replication and has demonstrated meaningful functional cure rates in combination therapy, the oral PD-L1 inhibitor AB-101 to boost host immune response, and lipid nanoparticle (LNP) delivery technology licensed to partners such as Alnylam Pharmaceuticals for enhanced therapeutic delivery. Founded in 2005 as part of a merger involving predecessors like Tekmira Pharmaceuticals, the company operates primarily in the United States with ongoing clinical trials spanning diverse administration routes and serves patients with unmet needs in virology, particularly cHBV. Recent developments include regaining global rights to imdusiran following the conclusion of its Greater China partnership with Qilu Pharmaceutical in 2025, which shifted strategy toward full control of the asset and long-term value creation despite near-term milestone revenue impacts; launching a late-stage clinical-focused Scientific Advisory Board with expert Dr. Harry Janssen; reporting positive Q2 2025 net income of $2.5 million driven by partnership wind-down; and preparing for a U.S. trial in March 2026 related to Moderna litigation, alongside continued advancement of its HBV portfolio into 2025 with solid financial positioning.
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Arbutus (ABUS) Q2 Revenue Surges 529%
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025